Pantoni Leonardo, Fierini Fabio, Poggesi Anna
Stroke Unit and Neurology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Cerebrovasc Dis. 2014;37(1):5-13. doi: 10.1159/000356796. Epub 2013 Dec 17.
Thrombolytic treatment is of proven benefit in acute ischemic stroke. The term cerebral small vessel disease (SVD) refers to a group of pathological processes affecting the small arteries, arterioles, venules and capillaries of the brain, and encompasses both ischemic and hemorrhagic lesions. Lacunar stroke, an expression of SVD, is associated with an unfavorable long-term prognosis for an increased risk of death, recurrent stroke and cognitive dysfunction. Nonetheless, the efficacy and safety of intravenous thrombolysis in patients with lacunar stroke has been debated for two main reasons. First, among all ischemic stroke subtypes, lacunar strokes have been considered the most benign. Second, the efficacy of a pharmacological reperfusion has been questioned given the absence of a clear demonstration of thrombosis. Intracerebral hemorrhage (ICH) remains the most devastating and unpredictable complication related to thrombolysis, and neuroimaging evidence of SVD is nowadays recognized as one of the risk factors for thrombolysis-related ICH.
This review is structured in two parts dealing with the questions whether or not patients with lacunar stroke or SVD should be treated with thrombolysis. In the first part, we revised the literature concerning the efficacy of thrombolysis in patients with acute lacunar stroke. We included two types of studies: those in which patients with lacunar stroke receiving recombinant human tissue plasminogen activator (rt-PA) were compared with lacunar stroke patients receiving placebo, and those in which a comparison was made among different stroke subtype patients treated with rt-PA. In the second part, we reviewed the available evidence on the risk of ICH in patients treated with thrombolysis for ischemic stroke and presenting with neuroimaging evidence of SVD such as white matter lesions (WML) and cerebral microbleeds. We further questioned the extent to which WML and microbleeds could be used as reliable predictors of ICH and the feasibility of their detection in an acute setting.
The studies herein reviewed show that thrombolysis is an effective treatment in acute lacunar stroke, and that the presence of cerebral SVD increases the risk of ICH during thrombolysis but does not represent an absolute exclusion criterion. In the future, it can be assumed that the use of MRI on a routine basis might lead to a better quantitative definition of SVD and its correlates, permitting a step forward in thrombolysis decision making.
溶栓治疗已被证明对急性缺血性卒中有益。脑小血管病(SVD)一词指的是影响脑内小动脉、小动脉、小静脉和毛细血管的一组病理过程,包括缺血性和出血性病变。腔隙性卒中是SVD的一种表现形式,与死亡、复发性卒中和认知功能障碍风险增加导致的不良长期预后相关。尽管如此,腔隙性卒中患者静脉溶栓的有效性和安全性一直存在争议,主要有两个原因。第一,在所有缺血性卒中亚型中,腔隙性卒中被认为是最良性的。第二,鉴于缺乏血栓形成的明确证据,药物再灌注的有效性受到质疑。脑出血(ICH)仍然是与溶栓相关的最具破坏性和不可预测的并发症,如今SVD的神经影像学证据被认为是溶栓相关ICH的危险因素之一。
本综述分为两部分,探讨腔隙性卒中或SVD患者是否应接受溶栓治疗的问题。在第一部分中,我们回顾了有关急性腔隙性卒中患者溶栓疗效的文献。我们纳入了两种类型的研究:将接受重组人组织型纤溶酶原激活剂(rt-PA)的腔隙性卒中患者与接受安慰剂的腔隙性卒中患者进行比较的研究,以及对接受rt-PA治疗的不同卒中亚型患者进行比较的研究。在第二部分中,我们回顾了有关缺血性卒中接受溶栓治疗且有SVD神经影像学证据(如白质病变(WML)和脑微出血)的患者发生ICH风险的现有证据。我们进一步质疑WML和微出血在多大程度上可作为ICH的可靠预测指标以及在急性情况下检测它们的可行性。
本文综述的研究表明,溶栓是急性腔隙性卒中的有效治疗方法,脑SVD的存在会增加溶栓期间ICH的风险,但并不代表绝对的排除标准。未来,可以设想常规使用MRI可能会导致对SVD及其相关因素有更好的定量定义,从而在溶栓决策方面向前迈进一步。